Cytokinetics CYTK
-
Cytokinetics ([[ CYTK ]] +6.7%) pops after saying the European Medicines Agency has granted its drug CK-2017357, its fast skeletal muscle troponin activator, orphan medicinal product designation for ...
Cytokinetics ( CYTK +6.7% ) pops after saying the European Medicines Agency has granted its drug CK-2017357, its fast skeletal muscle troponin activator, orphan medicinal product designation for the treatment of Lou Gehrig's Disease. Post your comment!
-
Cytokinetics ([[ CYTK ]] +2.5%) gains after Rodman & Renshaw initiates it with an outperform, saying the stock is "markedly undervalued," and a pure play in muscle biology that is "awaiting rediscovery ...
Cytokinetics ( CYTK +2.5% ) gains after Rodman & Renshaw initiates it with an outperform, saying the stock is "markedly undervalued," and a pure play in muscle biology that is "awaiting rediscovery by the investment community.” Post your comment!
-
Cytokinetics ([[ CYTK ]] +9%) trades higher late in the day after it says pre-clinical research relating to its program directed to the inhibition of smooth muscle myosin as a therapeutic approach for ...
Cytokinetics ( CYTK +9% ) trades higher late in the day after it says pre-clinical research relating to its program directed to the inhibition …
-
Cytokinetics' Promising Pipeline: Value Stock for a Long-Term Investor
… J.P. Zaragoza : Throughout this year, Cytokinetics ’ ( CYTK ) shares have been moving between $1.12 ..... what a long term investor should expect from Cytokinetics . What does Cytokinetics do? Cytokinetics develops clinical programs …
-
Cytokinetics , Inc. CYTK Q4 2010 Earnings Call Transcript
… afternoon and welcome ladies and gentlemen to the Cytokinetics Fourth Quarter and Yearend 2010 Conference Call ..... presentation. Good afternoon, and thank you for joining us Cytokinetics Senior Management team on this conference call today …
-
Dropping Coverage of Cytokinetics
We are no longer providing equity research on Cytokinetics CYTK . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.
-
Amgen to Develop Cytokinetics Drug
Cytokinetics CYTK announced that biotech giant Amgen ..... uncertainty surrounding the future of Cytokinetics ' lead drug candidate, we are keeping ..... terms of the agreement, Amgen will pay Cytokinetics a $50 million up-front licensing …
-
Cytokinetics Cuts Cancer Program
Cytokinetics CYTK announced Tuesday that it will reduce its workforce by 29% and discontinue development of all cancer-related products. The …
-
Cytokinetics Keeps Lid on 4Q Costs
Cytokinetics CYTK announced fourth-quarter and full ..... estimate unchanged. We're encouraged by Cytokinetics ' focus on tightening its research ..... million by 2010, the year prior to Cytokinetics ' first possible drug approval.
-
Cytokinetics Lowers Expense Outlook
Cytokinetics CYTK announced third-quarter results Wednesday ..... unchanged. We are encouraged that Cytokinetics lowered estimates for its research ..... GlaxoSmithKline GSK and Amgen AMGN, Cytokinetics is best served by focusing on only …